Asset Management One Co., Ltd. Neurocrine Biosciences Inc Transaction History

Asset Management One Co., Ltd.

$27.7 Billion
Q3 2024

A detailed history of Asset Management One Co., Ltd. transactions in Neurocrine Biosciences Inc stock. As of the latest transaction made, Asset Management One Co., Ltd. holds 69,230 shares of NBIX stock, worth $9.38 Million. This represents 0.03% of its overall portfolio holdings.

Number of Shares

69,230

Previous 67,525 2.52%

Holding current value

$9.38 Million

Previous $9.3 Million 14.26%

% of portfolio

0.03%

Previous 0.04%

22 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 30, 2024	BUY	$114.58 - $153.15 $195,358 - $261,120	1,705 Added 2.52%	69,230 $7.97 Million
Q2 2024 Jul 18, 2024	BUY	$130.86 - $143.19 $3.94 Million - $4.31 Million	30,096 Added 80.41%	67,525 $9.3 Million
Q1 2024 May 02, 2024	BUY	$130.4 - $143.74 $32,078 - $35,360	246 Added 0.66%	37,429 $5.16 Million
Q4 2023 Jan 24, 2024	SELL	$106.07 - $132.76 $156,877 - $196,352	-1,479 Reduced 3.83%	37,183 $4.9 Million
Q3 2023 Oct 19, 2023	BUY	$94.02 - $117.1 $19,462 - $24,239	207 Added 0.54%	38,662 $4.35 Million
Q2 2023 Jul 31, 2023	BUY	$89.53 - $104.87 $213,081 - $249,590	2,380 Added 6.6%	38,455 $3.63 Million
Q1 2023 Apr 25, 2023	BUY	$94.11 - $123.02 $13,928 - $18,206	148 Added 0.41%	36,075 $3.65 Million
Q4 2022 Feb 06, 2023	SELL	$106.72 - $127.06 $224,325 - $267,080	-2,102 Reduced 5.53%	35,927 $4.29 Million
Q3 2022 Nov 04, 2022	BUY	$92.03 - $107.81 $5,337 - $6,252	58 Added 0.15%	38,029 $4.04 Million
Q2 2022 Jul 29, 2022	SELL	$75.79 - $100.07 $151 - $200	-2 Reduced 0.01%	37,971 $3.7 Million
Q1 2022 May 13, 2022	SELL	$72.45 - $94.81 $46,368 - $60,678	-640 Reduced 1.66%	37,973 $3.56 Million
Q4 2021 Feb 09, 2022	SELL	$79.65 - $106.22 $47,949 - $63,944	-602 Reduced 1.54%	38,613 $3.25 Million
Q3 2021 Nov 02, 2021	BUY	$86.18 - $99.03 $14,305 - $16,438	166 Added 0.43%	39,215 $3.76 Million
Q2 2021 Aug 03, 2021	SELL	$89.43 - $102.27 $93,454 - $106,872	-1,045 Reduced 2.61%	39,049 $3.8 Million
Q1 2021 May 14, 2021	SELL	$87.57 - $119.4 $274,531 - $374,319	-3,135 Reduced 7.25%	40,094 $3.9 Million
Q4 2020 Feb 12, 2021	SELL	$86.91 - $108.33 $703,101 - $876,389	-8,090 Reduced 15.76%	43,229 $4.07 Million
Q3 2020 Nov 13, 2020	SELL	$96.16 - $135.15 $32,598 - $45,815	-339 Reduced 0.66%	51,319 $4.94 Million
Q2 2020 Aug 14, 2020	BUY	$85.09 - $130.36 $729,136 - $1.12 Million	8,569 Added 19.89%	51,658 $6.31 Million
Q1 2020 May 14, 2020	SELL	$75.11 - $113.76 $1.15 Million - $1.74 Million	-15,270 Reduced 26.17%	43,089 $3.73 Million
Q4 2019 Feb 14, 2020	BUY	$86.8 - $118.57 $3.68 Million - $5.03 Million	42,389 Added 265.43%	58,359 $6.27 Million
Q2 2019 Aug 14, 2019	BUY	$72.24 - $91.27 $391,468 - $494,592	5,419 Added 51.36%	15,970 $1.35 Million
Q1 2019 May 15, 2019	BUY	$69.31 - $91.53 $731,289 - $965,733	10,551 New	10,551 $930,000

Others Institutions Holding NBIX

# of Institutions

626

Shares Held

94M

Call Options Held

632K

Put Options Held

621K

View Full List

About NEUROCRINE BIOSCIENCES INC

Ticker NBIX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 95,639,296
Market Cap $13B
Description
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, endocrine, and psychiatric disorders. The company's portfolio includes treatments for tardive dyskinesia, Parkinson's disease, endometriosis, and uterine fibroids, as well as clinical programs in various therapeutic areas. Its lead asset is INGREZZA, ...

More about NBIX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Asset Management One Co., Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Asset Management One Co., Ltd. with notifications on news.

Account

Asset Management One Co., Ltd. Neurocrine Biosciences Inc Transaction History